Form 4: Akero Therapeutics Chief Development Officer Executes Pre-Arranged Stock Option Exercise and Sale

Akero Therapeutics, Inc.'s Chief Development Officer, Catriona Yale, completed a pre-scheduled exercise of stock options and subsequent sale of common stock, realizing a significant gain.

Summary

• Catriona Yale, Chief Development Officer of Akero Therapeutics, Inc. (AKRO), engaged in transactions involving the company's common stock on July 16, 2025.
• Ms. Yale acquired 10,000 shares of common stock by exercising stock options at a price of $19.87 per share.
• Immediately following the option exercise, she sold a total of 10,000 shares of common stock in two separate transactions.
• The first sale involved 8,658 shares at a weighted-average price of $52.865 per share, with prices ranging from $52.34 to $53.31.
• The second sale involved 1,342 shares at a weighted-average price of $53.474 per share, with prices ranging from $53.35 to $53.58.
• All reported transactions were executed pursuant to a Rule 10b5-1 trading plan established on May 24, 2024.
• Following these transactions, Ms. Yale's direct beneficial ownership of common stock is 91,488 shares, and she holds 131,205 stock options.

Sentiment

Score: 6

Explanation: The sentiment is neutral to slightly positive. While an insider sold shares, it was a pre-arranged transaction (10b5-1 plan) for liquidity and profit realization from option exercise, which is a common and expected event. It does not signal a negative outlook on the company's future.

Positives

• The Chief Development Officer realized a substantial profit by exercising options at $19.87 and selling shares at weighted-average prices of $52.865 and $53.474.
• The transactions were conducted under a pre-arranged Rule 10b5-1 trading plan, indicating a planned liquidity event rather than a reaction to new material non-public information.

Negatives

• An insider selling shares, even under a 10b5-1 plan, can sometimes be perceived by the market as a lack of confidence, though this is mitigated by the pre-arranged nature and the fact that it's an option exercise and sell.

Future Outlook

This Form 4 filing does not provide forward-looking statements or guidance regarding the company's future performance or strategic outlook.

Industry Context

Insider transactions, such as option exercises and subsequent share sales, are common occurrences in publicly traded companies, particularly in the biotechnology sector where executive compensation often includes significant equity components. The use of a Rule 10b5-1 plan is a standard practice for insiders to manage their equity holdings in a compliant manner.

Stakeholder Impact

• Shareholders: The transaction represents a liquidity event for a key executive, which is a normal part of compensation. The sale of shares, even if pre-arranged, might be observed by investors, but the 10b5-1 plan mitigates concerns about opportunistic selling.

Key Dates

Keywords

Akero Therapeutics, AKRO, Form 4, Insider Trading, Stock Option Exercise, Share Sale, 10b5-1 Plan, Chief Development Officer, Beneficial Ownership